mrt67307 cas 1190378-57-4

Chemical Name: MRT67307
CAS No: 1190378-57-4
Molecular Formula: C26H36N6O2
Molecular Weight: 465
Appearance: White to off-white (Solid)
Assay: 98%

  ... 正在查看此商品

  分享
Guaranteed Safe Checkout

Table of Contents

1. Product Overview & Specifications

Parameter MRT67307 (CAS 1190378-57-4) Comparable Inhibitors
Chemical Name 8-(6-Phenylhexyl)-2-(2-propen-1-yl)-1,3,8-triazaspiro[4.5]decan-4-one Amlexanox, BX795
Molecular Formula C23H33N3O Varies by compound
Molecular Weight 367.53 g/mol 268.27 g/mol (Amlexanox)
Targets TBK1/IKKε (IC50 = 19 nM/160 nM) IKKε/TBK1 (Amlexanox IC50 = 1.8 μM/8.8 μM)
Solubility DMSO: 30 mg/mL, Water: <0.1 mg/mL DMSO-soluble standard
Storage -20°C, desiccated Similar storage conditions

2. Key Applications & Research Uses

Core Research Applications:

  • Inhibition of IRF3 phosphorylation in innate immunity studies
  • Selective suppression of IFN-β production in viral infection models
  • Investigation of autophagy regulation pathways
  • Metabolic disease research through TBK1/IKKε pathway modulation

Technical Advantages:

  • 10x greater selectivity for TBK1 vs. IKKε compared to earlier inhibitors
  • Effective in primary cell cultures at 1-10 μM concentrations
  • Minimal off-target effects on related kinases (IKKα/β, JNK, p38)

3. Usage Guidelines & Protocols

Standard Experimental Protocol:

  1. Prepare stock solution in DMSO at 10 mM concentration
  2. Dilute in culture medium to final concentration (1-10 μM typical)
  3. Treat cells for 4-24 hours depending on experimental design
  4. Combine with viral infection (e.g., HSV-1) or cytokine stimulation

Optimization Tips:

  • Pre-test cytotoxicity using MTT assay (recommended range: 0.1-50 μM)
  • Combine with IFN-β ELISA for pathway validation
  • Use fresh DMSO stocks to prevent compound degradation

4. Client Case Studies

Case Study 1: Virology Research Group

  • Client: University of Medical Sciences, Europe
  • Application: HSV-1 antiviral mechanism investigation
  • Result: 78% reduction in viral replication at 5 μM concentration
  • Protocol: 8-hour pre-treatment + 24h post-infection analysis

Case Study 2: Oncology Drug Development

  • Client: BioPharma Solutions Inc., USA
  • Application: NSCLC combination therapy screening
  • Result: Synergy with PD-1 inhibitors (CI=0.62 at 3 μM)
  • Outcome: Phase II trial candidate selection

5. Request Customized Solutions

For bulk orders or formulation optimization:

  • Email: info@vivalr.com
  • Phone: (86) 15866781826

Technical support available for:

  • Custom concentration formulations
  • GMP-grade production batches
  • Stability testing documentation
0.00
0 条评论
5
0
4
0
3
0
2
0
1
0
成为第一个评论 “mrt67307 cas 1190378-57-4”

您的邮箱地址不会被公开。 必填项已用 * 标注

这是必填栏。

这是必填栏。

这是必填栏。

评论

目前还没有评论。

类别 
我的购物车
愿望清单
最近浏览
类别
Wait! before you leave…
Get 30% off for your first order
CODE30OFFCopy to clipboard
Use above code to get 30% off for your first order when checkout
比较产品 (0 产品)